Perfuse Therapeutics Announces Initiation of Enrollment to the Phase 2A Clinical Trial of PER001 Intravitreal Implant in Diabetic Retinopathy
Excerpt from the Press Release:
SAN FRANCISCO, Aug. 3, 2023 /PRNewswire/ — Perfuse Therapeutics, a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases is pleased to announce the initiation of enrollment into the Ph2a clinical trial of PER-001 intravitreal implant in Diabetic Retinopathy.
The Phase 2a trial is a patient masked, randomized, sham-controlled study that will evaluate the safety and tolerability of two doses of PER-001 Intravitreal Implant in patients with Diabetic Retinopathy. The Company is also evaluating PER-001 intravitreal implant in a Ph1/2a clinical trial in patients with Glaucoma.
“The initiation of this trial is a significant milestone for patients, the retina community and Perfuse, as we continue to advance in the clinic with a potentially disease-modifying treatment for diabetic retinopathy. Rapid advancement into multiple Ph2a studies is a testament to the skill and dedication of our team and underscores the broad potential of our intravitreal sustained release PER-001 implant in all retinal diseases driven by ischemia”, said Sevgi Gurkan, M.D., Founder and CEO of Perfuse.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?